Rheumatoid arthritis vaccine (IR 501) - Immune Response BioPharma

Drug Profile

Rheumatoid arthritis vaccine (IR 501) - Immune Response BioPharma

Alternative Names: AI 201; AI 204; AI 205; IR 201; IR 501; IR 703; RAVAX; Zyvac-RA

Latest Information Update: 10 Sep 2015

Price : $50

At a glance

  • Originator Immune Response Corporation
  • Developer Immune Response BioPharma
  • Class Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Rheumatoid arthritis

Most Recent Events

  • 18 May 2015 The vaccine is still in phase-III development for Rheumatoid arthritis in USA
  • 04 Feb 2014 Ravax™ is still in phase III development for Rheumatoid arthritis in USA
  • 25 Jun 2012 Phase-III clinical trials in Rheumatoid arthritis in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top